论文部分内容阅读
医药产业供应链正在发生着某种新的变化。2002年以来,多家上市公司投入巨资,或并购重组医药流通企业,或斥资建设医药销售网络和渠道,强势介入医药流通行业。让人们感到惊异的是,很多投资者原来并不是从事医药行业的,如去年初,北京出租车行业骨干企业——银建实业股份有限公司开始涉足首都医药零售行业;而在更早的2001年,房地产“巨头”保刺集团就已大举进军医药领域,香港地产四大巨鳄之一的新世界集两也早已进入云南医药市场。显然,他们都是为了医药供应链中包含的巨大利益而来。
The pharmaceutical industry supply chain is undergoing some new changes. Since 2002, a number of listed companies have invested heavily in or merged and reorganized pharmaceutical distribution companies, or invested in the construction of pharmaceutical sales networks and channels, becoming strongly involved in the pharmaceutical distribution industry. To the surprise of many investors, many investors were not originally engaged in the pharmaceutical industry. For example, at the beginning of last year, Silver Building Industry Co., Ltd., the backbone of Beijing’s taxi industry, started to set foot in the capital medical retail industry. In the earlier 2001 , Real estate “giant” Paul Thorn Group has massively entered the field of medicine, the Hong Kong real estate one of the four giant New World set of two has long been entered the Yunnan pharmaceutical market. Obviously, they are all coming for the great benefit contained in the pharmaceutical supply chain.